Nicola Baker-Munton
Vorstandsvorsitzender bei Stratagem Intellectual Property Management Ltd.
Profil
Nicola Baker-Munton is the founder of Stratagem IPM, which was founded in 1999.
He is currently the CEO of Stratagem Intellectual Property Management Ltd.
and a Non-Executive Director at Cypralis Ltd.
Aktive Positionen von Nicola Baker-Munton
| Unternehmen | Position | Beginn |
|---|---|---|
Cypralis Ltd.
 Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Stratagem Intellectual Property Management Ltd.
 Stratagem Intellectual Property Management Ltd. Miscellaneous Commercial ServicesCommercial Services Stratagem Intellectual Property Management Ltd. manages patent and copyright agencies. The private company is based in Cambridge, UK. The British company was founded in 1999. The CEO is Nicola Baker-Munton. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Nicola Baker-Munton
| Unternehmen | Position | Ende |
|---|---|---|
| Stratagem IPM | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
| Stratagem IPM | |
Stratagem Intellectual Property Management Ltd.
Stratagem Intellectual Property Management Ltd. Miscellaneous Commercial ServicesCommercial Services Stratagem Intellectual Property Management Ltd. manages patent and copyright agencies. The private company is based in Cambridge, UK. The British company was founded in 1999. The CEO is Nicola Baker-Munton. | Commercial Services |
Cypralis Ltd.
Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Health Technology |
